Genomics bioinformatics platform developer PierianDx, a Washington University in St Louis spinout, has raised fresh capital to advance its business strategy.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

University of Pennsylvania returned for a series B round that boosted its immunotherapy spinout's overall funding to $231m.

Gilead Sciences and Be The Match BioTherapies returned for a series B round that boosted the immunotherapy developer's overall funding to $231m.

The Alphabet unit formerly known as Google Ventures has strengthened its cancer care by bringing ex-Tesaro head of R&D Sridhar Ramaswamy as an entrepreneur-in-residence.

The Celgene and GV-backed small molecule drug developer floated at the bottom of its range, raising less than half the target it set last week.

University of Pennsylvania spinout Cabaletta has gone public after raising $74.8m in an initial public offering on the Nasdaq Global Select Market.

Prime Medicine will work alongside Harvard University-founded Beam Therapeutics to commercialise Broad Institute faculty vice-chair David Liu's single-base DNA editing inventions.

Tasly and Genexine-backed I-Mab has filed to raise up to $100m that will fund development of its autoimmune disorder and cancer drugs.